Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SB-265610 (GSK-CXCR2) 是竞争性非肽变构CXCR2选择性拮抗剂,可阻断大鼠 CINC-1 诱导的钙动员和中性粒细胞趋化性,IC50分别为 3.7 和 70 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 495 | 现货 | ||
5 mg | ¥ 1,230 | 现货 | ||
10 mg | ¥ 1,990 | 现货 | ||
25 mg | ¥ 3,370 | 现货 | ||
50 mg | ¥ 4,880 | 现货 | ||
100 mg | ¥ 6,990 | 现货 | ||
500 mg | ¥ 13,800 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,370 | 现货 |
产品描述 | SB-265610 (GSK-CXCR2) is a nonpeptide and allosteric CXCR2 antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization and neutrophil chemotaxis (IC50s: 3.7 nM and 70 nM, respectively). |
靶点活性 | CXCR2(CINC-1-induced calcium mobilization):3.7 nM, CXCR2(neutrophil chemotaxis):70 nM |
体外活性 | SB-265610 decreases the antiapoptotic effect of CINC-1 to the levels of those untreated with CINC-1. SB-265610 antagonizes rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization (IC50 of 3.7 nM) and rat neutrophil chemotaxis in a concentration-dependent manner (IC50 of 70 nM) [1]. |
体内活性 | SB-265610 (100 mg/kg/day;p.o; daily; for 5 days; CXCR2 wild type mice) treatment markedly delays healing parameters in CXCR2 wild type mice during the wound repair process[2]. |
别名 | GSK-CXCR2 |
分子量 | 357.16 |
分子式 | C14H9BrN6O |
CAS No. | 211096-49-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 66 mg/mL (184.79 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.7999 mL | 13.9993 mL | 27.9987 mL | 69.9966 mL |
5 mM | 0.56 mL | 2.7999 mL | 5.5997 mL | 13.9993 mL | |
10 mM | 0.28 mL | 1.3999 mL | 2.7999 mL | 6.9997 mL | |
20 mM | 0.14 mL | 0.7 mL | 1.3999 mL | 3.4998 mL | |
50 mM | 0.056 mL | 0.28 mL | 0.56 mL | 1.3999 mL | |
100 mM | 0.028 mL | 0.14 mL | 0.28 mL | 0.7 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SB-265610 211096-49-0 Autophagy GPCR/G Protein Immunology/Inflammation CXCR nonpeptide inhibit Inhibitor inflammation recruitment SB 265610 Delay healing neutrophil wound CXC chemokine receptors GSK-CXCR2 SB265610 inhibitor